South & Central America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel

The South & Central America glaucoma therapeutics market was valued at US$ 352.85 million in 2023 and is expected to reach US$ 428.75 million by 2031; it is estimated to register a CAGR of 2.5% from 2023 to 2031.

Development of Wearable Technologies Fuels South & Central America Glaucoma Therapeutics Market

Technological innovation has always been fundamental to any discipline of life sciences, including ophthalmology, as modern devices are key to accurate diagnosis and improved treatments. Advancements in treatments have enabled the improved treatment of glaucoma. Wearable glaucoma diagnostics and therapeutics products have emerged as potential solutions. Conventional diagnostic techniques provide reliable intraocular pressure data, while innovative contact lenses such as Sensimed Triggerfish offer continuous IOP tracking. Advanced drug-eluting contact lenses are also emerging as a potential solution for glaucoma therapy. n March 2023, SpyGlass Pharma released 6-month data from its first-in-human glaucoma treatment trial. The data shows that its new drug delivery platform, which is a single-piece, hydrophobic acrylic intraocular lens with drug-eluting pads, continues to significantly lower IOP in patients suffering from glaucoma or ocular hypertension. Thus, the development of such modern wearable products is likely to propel the demand for glaucoma therapeutics in the coming years.

South & Central America Glaucoma Therapeutics Market Overview

The South & Central America glaucoma therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to have a significant market share in this region. Also, it is projected to record the highest growth rate. In Brazil, POAG is the most common type of glaucoma, accounting for ~80% of cases. Developing healthcare facilities, rising prevalence of glaucoma, and growing R&D activities by research organizations in the region are expected to contribute to the rapid growth of the glaucoma therapeutics market. According to an article published in SciELOBrazil in February 2021, glaucoma was the leading cause of blindness in Brazil. By 2030, an estimated 95.4 million people in Brazil will have glaucoma. Numerous ophthalmology conferences are being held in the country, which aid in exploring different technologies in the medical field. In addition, the demand for glaucoma therapeutics is rising due to growing medical tourism in the country. Brazil has multiple Joint Commission International (JCI)-accredited hospitals that meet global standards. These hospitals have advanced medical technology and highly skilled professionals, and they offer various specialties, including ophthalmology, noninvasive surgeries, and cardiology. According to an article published in the VHL Regional Portal in May 2023, a study of patients referred by general ophthalmologists to the clinic for suspected glaucoma at a tertiary public hospital in southern Brazil from March 2016 to December 2018 was conducted. The study, including 135 patients from other countries, concluded that the patients with the normal tension glaucoma had a more advanced stage of the disease at the time of diagnosis. This signifies that patients from developed countries are traveling to developing countries such as Brazil to seek advanced medical diagnoses and treatments offered by the country.

Brazil is experiencing a rise in the geriatric population, which is expected to increase the demand for ophthalmology products. In 2020, the elderly population was 30.1 million, representing ~14.3% of the population. The Brazilian Institute of Geography and Statistics (IBGE) estimates (2019) show that this age group will grow at a rate of 3.6% per year, reaching 73.4 million by 2060, which will be equal to 32.2% of the population. Thus, growing medical tourism and rising geriatric population are expected to propel the market growth during the forecast period.

South & Central America Glaucoma Therapeutics Market Segmentation

The South & Central America glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the South & Central America glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the South & Central America glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the South & Central America glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the South & Central America glaucoma therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the South & Central America glaucoma therapeutics market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America glaucoma therapeutics market.
• Highlights key business priorities to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the South & Central America glaucoma therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America glaucoma therapeutics market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.